Edition:
United Kingdom

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

3.97USD
19 Jan 2018
Change (% chg)

$0.07 (+1.79%)
Prev Close
$3.90
Open
$3.89
Day's High
$3.99
Day's Low
$3.87
Volume
247,894
Avg. Vol
301,446
52-wk High
$5.44
52-wk Low
$3.20

Latest Key Developments (Source: Significant Developments)

Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Agenus Inc ::AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS.AGENUS INC - TRANSACTION IS COMPRISED OF $190 MILLION OF CASH PROCEEDS AT CLOSING PLUS UP TO $40 MILLION IN MILESTONE PAYMENTS.AGENUS INC - AGENUS WILL USE PART OF THE PROCEEDS TO REDEEM ITS ROYALTY BOND FROM OBERLAND, AMONG OTHERS.AGENUS INC - IN EVENT THAT CERTAIN SALES MILESTONES ARE NOT MET, AGENUS WILL OWE HCR APPROXIMATELY $26 MILLION IN 2021.  Full Article

Agenus reports Q3 loss per share $0.37
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Agenus Inc :Agenus reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.37.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Agenus Inc - ‍Cash, cash equivalents and short-term investments were $70.1 million at Sept 30, 2017 compared to $76.4 million as of Dec 31, 2016​.Agenus Inc - Qtrly revenue $3.4 million versus $4.4 mln‍​.  Full Article

Agenus files for mixed shelf of up to $250 million
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Agenus Inc :Agenus Inc files for mixed shelf of up to $250 million – SEC filing‍​.  Full Article

Venbio Select Advisor LLC reports a 5.41 pct passive stake in Agenus
Thursday, 9 Feb 2017 

Agenus Inc :Venbio Select Advisor Llc reports a 5.41 passive stake in Agenus Inc as on December 31, 2016 - sec filing.  Full Article

Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine
Tuesday, 17 Jan 2017 

Agenus Inc : Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine .Agenus says under collaboration, Agenus will supply Prophage, Merck will provide pembrolizumab and NCI and BTTC member sites will recruit patients and conduct trial.  Full Article

Agenus Q2 loss per share $0.33
Thursday, 28 Jul 2016 

Agenus Inc : Qtrly revenue $6.6 million versus $6.4 million . Agenus reports second quarter 2016 financial results and operational progress . Q2 loss per share $0.33 . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S .Q2 revenue view $5.1 million -- Thomson Reuters I/B/E/S.  Full Article

Agenus' chief financial officer, C.Evan Ballantyne to resign
Tuesday, 19 Jul 2016 

Agenus Inc : On july 14, 2016, C. Evan Ballantyne, chief financial officer informed agenus of his intention to resign - sec filing .Christin Klaskin, Agenus' VP, finance and principal accounting officer, will retain her roles, assume role of principal financial officer.  Full Article

Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody
Wednesday, 22 Jun 2016 

Agenus Inc : Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months .Agenus announces commencement of phase 1/2 clinical trial of anti-GITR checkpoint antibody INCAGN1876 in patients with solid tumors.  Full Article

BRIEF-Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners

* AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS